Aprea Therapeutics, Inc. (APRE) скачать в хорошем качестве

Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania. The company focuses on precision oncology through synthetic lethality, aiming to develop novel cancer therapeutics that target DNA damage response (DDR) pathways. The current stock price is approximately $1.81, with an intraday range from $1.83 to $2.00. The company has a market capitalization of about $10.73 million and employs 8 people. Pipeline Overview: ATRN-119: A first-in-class macrocyclic ATR inhibitor in Phase 1/2a trials (ABOYA-119) for patients with advanced solid tumors harboring specific genetic mutations. Early signs of anti-tumor activity have been observed. APR-1051: An oral WEE1 inhibitor in Phase 1 trials (ACESOT-1051) targeting cancers with Cyclin E overexpression and other biomarkers. Preliminary results indicate good tolerability with no unexpected toxicities. Financials: Revenue (FY 2024): $1.5 million Net Income (FY 2024): -$12.96 million Aprea Therapeutics is advancing its clinical programs focused on targeted cancer therapies for genetically defined patient populations. References: Aprea Therapeutics LinkedIn BioSpace: Aprea Therapeutics Q3 2024 Financial Results Aprea Therapeutics Official Website